354 related articles for article (PubMed ID: 34505396)
1. Severe anaphylaxis caused by intravenous anti-cancer drugs.
Horita N; Miyagi E; Mizushima T; Hagihara M; Hata C; Hattori Y; Hayashi N; Irie K; Ishikawa H; Kawabata Y; Kitani Y; Kobayashi N; Kobayashi N; Kurita Y; Miyake Y; Miyake K; Oguri S; Ota I; Shimizu A; Takeuchi M; Yamada A; Yamamoto K; Yukawa N; Masuda M; Oridate N; Ichikawa Y; Kaneko T
Cancer Med; 2021 Oct; 10(20):7174-7183. PubMed ID: 34505396
[TBL] [Abstract][Full Text] [Related]
2. Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer.
Ishida S; Masuguchi K; Kawashiri T; Tsuji T; Watanabe H; Akiyoshi S; Kubo M; Masuda S; Egashira N
Biol Pharm Bull; 2020; 43(4):663-668. PubMed ID: 32238707
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis to intravenous gelatin-based solutions: a case series examining clinical features and severity.
Farooque S; Kenny M; Marshall SD
Anaesthesia; 2019 Feb; 74(2):174-179. PubMed ID: 30520028
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer.
Iwamoto T; Yuta A; Tabata T; Sugimoto H; Gabazza EC; Hirai H; Kojima S; Okuda M
Biol Pharm Bull; 2012; 35(9):1487-95. PubMed ID: 22975499
[TBL] [Abstract][Full Text] [Related]
7. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Markman M; Zanotti K; Kulp B; Peterson G; Markman M
Gynecol Oncol; 2003 Jun; 89(3):514-6. PubMed ID: 12798720
[TBL] [Abstract][Full Text] [Related]
8. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
[TBL] [Abstract][Full Text] [Related]
9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Wu HL
J Oncol Pharm Pract; 2019 Sep; 25(6):1388-1395. PubMed ID: 30176784
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Basophil CD203c as a Biomarker for Predicting the Timing of Hypersensitivity Reaction in Carboplatin Rechallenge: Three Case Reports.
Iwamoto T; Sugimoto H; Tabata T; Okuda M
Clin Ther; 2016 Jun; 38(6):1537-1541. PubMed ID: 27181615
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
13. Drug fever induced by carboplatin-based regimens: Higher incidence in a women's hospital.
Zhang X; Zhao M; Zheng C
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):882-887. PubMed ID: 34507666
[TBL] [Abstract][Full Text] [Related]
14. Anaphylaxis from intraperitoneal infusion of cisplatin: a case report.
Ozgüroglu M; Demir G; Demirelli F; Mandel NM
Am J Clin Oncol; 1999 Apr; 22(2):172-3. PubMed ID: 10199453
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Polyzos A; Tsavaris N; Kosmas C; Arnaouti T; Kalahanis N; Tsigris C; Giannopoulos A; Karatzas G; Giannikos L; Sfikakis PP
Oncology; 2001; 61(2):129-33. PubMed ID: 11528251
[TBL] [Abstract][Full Text] [Related]
17. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.
Ciesielski-Carlucci C; Leong P; Jacobs C
Am J Clin Oncol; 1997 Aug; 20(4):373-5. PubMed ID: 9256892
[TBL] [Abstract][Full Text] [Related]
18. Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.
Weiss J; Grilley Olson J; Deal AM; Chera B; Weissler M; Murphy BA; Hayes DN; Gilbert J
Cancer; 2016 Jun; 122(11):1697-701. PubMed ID: 26989991
[TBL] [Abstract][Full Text] [Related]
19. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
